noemi arrighetti

Dr. noemi arrighetti

IRCCS Istituto Nazionale dei Tumori
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in Biomaterials
Verified
Journal Article
Closed access
Alessandro ParodiAlessandro Parodi
Alessandro Parodi
Roberto MolinaroRoberto Molinaro
Roberto Molinaro
MSManuela Sushnitha
Manuela Sushnitha
MEMichael Evangelopoulos
Michael Evangelopoulos
JMJonathan O. Martinez
Jonathan O. Martinez
ETEnnio Tasciotti
Ennio Tasciotti

2 December 2019 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
NAnoemi arrighetti
noemi arrighetti
CCClaudia Corbo
Claudia Corbo
MEMichael Evangelopoulos
Michael Evangelopoulos
APAnna Pastò
Anna Pastò
VZValentina Zuco
Valentina Zuco
ETEnnio Tasciotti
Ennio Tasciotti
Cancer treatment still represents a formidable challenge, despite substantial advancements in available therapies being made over the past decade. One major issue is poor therapeutic efficacy due to lack of specificity and low bioavailability. The progress of nanotechnology and the development of a variety of nanoplatforms have had a significant impact in improving the therapeutic outcome of chemotherapeutics. Nanoparticles can overcome various biological barriers and localize at tumor site, while simultaneously protecting a therapeutic cargo and increasing its circulation time. Despite this, due to their synthetic origin, nanoparticles are often detected by the immune system and preferentially sequestered by filtering organs. Exosomes have recently been investigated as suitable substitutes for the shortcomings of nanoparticles due to their biological compatibility and particularly small size (i.e., 30-150 nm). In addition, exosomes have been found to play important roles in cell communication, acting as natural carriers of biological cargoes throughout the body. This review aims to highlight the use of exosomes as drug delivery vehicles for cancer and showcases the various attempts used to exploit exosomes with a focus on the delivery of chemotherapeutics and nucleic acids.

7 November 2019 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
Roberto MolinaroRoberto Molinaro
Roberto Molinaro
JMJonathan O. Martinez
Jonathan O. Martinez
AZAssaf Zinger
Assaf Zinger
Alessandro De VitaAlessandro De Vita
Alessandro De Vita
GSGianluca Storci
Gianluca Storci
ETEnnio Tasciotti
Ennio Tasciotti
Biomimetic nanovesicles deriving from leukocytes membrane proteins, called leukosomes, exhibit increased targeting of cancer vasculature and stroma by exploiting the inflammatory pathway responsible for recruiting immune cells to the cancer lesion.


3 June 2024 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
YKYaniv Kazansky
Yaniv Kazansky
DCDaniel Cameron
Daniel Cameron
HMHelen S. Mueller
Helen S. Mueller
PDPhillip Demarest
Phillip Demarest
Nadia ZaffaroniNadia Zaffaroni
Nadia Zaffaroni
AKAlex Kentsis
Alex Kentsis
Epigenetic dependencies have become evident in many cancers. On the basis of antagonism between BAF/SWI-SNF and PRC2 in SMARCB1-deficient sarcomas, we recently completed the clinical trial of the EZH2 inhibitor tazemetostat. However, the principles of tumor response to epigenetic therapy in general, and tazemetostat in particular, remain unknown. Using functional genomics and diverse experimental models, we define molecular mechanisms of tazemetostat resistance in SMARCB1-deficient tumors. We found distinct acquired mutations that converge on the RB1/E2F axis and decouple EZH2-dependent differentiation and cell-cycle control. This allows tumor cells to escape tazemetostat-induced G1 arrest, suggests a general mechanism for effective therapy, and provides prospective biomarkers for therapy stratification, including PRICKLE1. On the basis of this, we develop a combination strategy to circumvent tazemetostat resistance using bypass targeting of AURKB. This offers a paradigm for rational epigenetic combination therapy suitable for translation to clinical trials for epithelioid sarcomas, rhabdoid tumors, and other epigenetically dysregulated cancers. Significance: Genomic studies of patient epithelioid sarcomas and rhabdoid tumors identify mutations converging on a common pathway for response to EZH2 inhibition. Resistance mutations decouple drug-induced differentiation from cell-cycle control. We identify an epigenetic combination strategy to overcome resistance and improve durability of response, supporting its investigation in clinical trials. See related commentary by Paolini and Souroullas, p. 903. This article is featured in Selected Articles from This Issue, p. 897

13 March 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
NAnoemi arrighetti
noemi arrighetti
GBGiovanni Luca Beretta
Giovanni Luca Beretta
Prostate cancer (PCa) is the fifth cause of tumor-related deaths in man worldwide. Despite the considerable improvement in the clinical management of PCa, several limitations emerged both in the screening for early diagnosis and in the medical treatment. The use of prostate-specific antigen (PSA)-based screening resulted in patients’ overtreatment and the standard therapy of patients suffering from locally advanced/metastatic tumors (e.g., radical prostatectomy, radiotherapy, and androgen deprivation therapy) showed time-limited efficacy with patients undergoing progression toward the lethal metastatic castration-resistant PCa (mCRPC). Although valuable alternative therapeutic options have been recently proposed (e.g., docetaxel, cabazitaxel, abiraterone, enzalutamide, and sipuleucel-T), mCRPC remains incurable. Based on this background, there is an urgent need to identify new and more accurate prostate-specific biomarkers for PCa diagnosis and prognosis and to develop innovative medical approaches to counteract mCRPC. In this context, microRNA (miRNAs) emerged as potential biomarkers in prostate tissues and biological fluids and appeared to be promising therapeutic targets/tools for cancer therapy. Here we overview the recent literature and summarize the achievements of using miRNAs as biomarkers and therapeutic targets/tools for fighting PCa.